Assessing the cardiac safety of ebastine. Epilogue.
Roberts
D J
DJ
Scientific and Regulatory Affairs, Almirall Prodesfarma, Barcelona, Spain.
D000818:Animals; D002090:Butyrophenones / Q000009:adverse effects* / Q000494:pharmacology; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006634:Histamine H1 Antagonists / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D010880:Piperidines / Q000009:adverse effects* / Q000494:pharmacology; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000453:epidemiology; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG
D002090:Butyrophenones; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006634:Histamine H1 Antagonists; C092509:KCNH6 protein, human; D010880:Piperidines; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; C058249:ebastine